<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109284</article-id><article-id pub-id-type="publisher-id">ACM-37531</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_95111437.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  房颤导管消融成功后抗凝
  Anticoagulation after Successful Catheter Ablation of Atrial Fibrillation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>丽娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>汪</surname><given-names>敏</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>双</surname><given-names>东思</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>武汉亚洲心脏病医院，湖北 武汉</addr-line></aff><aff id="aff2"><addr-line>武汉科技大学医学院，湖北 武汉</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>1892</fpage><lpage>1898</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    房颤患者有发生脑血管栓塞事件(cerebrovascular embolic events, CVEs)的风险，包括卒中和短暂性脑缺血发作。口服抗凝药物治疗(oral anticoagulation therapy, OAT)可以有效地预防CVE，而导管消融(catheter ablation, CA)治疗房颤已成为部分患者最有效的节律控制策略。尽管有回顾性研究认为通过CA消除房颤或减轻房颤负担可能会显著降低卒中风险，然而在导管消融成功后是否可以安全地停止OAT仍然是一个有争议的话题。
    Patients with atrial fibrillation are at risk for thromboembolic events (cerebrovascularembolicevents, CVEs), including stroke and transient ischemic attacks. Anticoagulant therapy (oralanticoagulation therapy, OAT) can effectively prevent CVE, catheter ablation (catheterablation, CA) in the treatment of atrial fibrillation has become the most effective rhythm control strategy for some patients. Although retrospective studies have suggested that eliminating atrial fibrillation or reducing the burden of atrial fibrillation through CA may significantly reduce stroke risk, whether OAT can be stopped safely after successful catheter ablation is still a controversial topic. 
  
 
</p></abstract><kwd-group><kwd>心房颤动，导管消融，口服抗凝停止，卒中, Atrial Fibrillation</kwd><kwd> Catheter Ablation</kwd><kwd> Anticoagulant</kwd><kwd> Stroke</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>房颤患者有发生脑血管栓塞事件(cerebrovascular embolic events, CVEs)的风险，包括卒中和短暂性脑缺血发作。口服抗凝药物治疗(oral anticoagulation therapy, OAT)可以有效地预防CVE，而导管消融(catheter ablation, CA)治疗房颤已成为部分患者最有效的节律控制策略。尽管有回顾性研究认为通过CA消除房颤或减轻房颤负担可能会显著降低卒中风险，然而在导管消融成功后是否可以安全地停止OAT仍然是一个有争议的话题。</p></sec><sec id="s2"><title>关键词</title><p>心房颤动，导管消融，口服抗凝停止，卒中</p></sec><sec id="s3"><title>Anticoagulation after Successful Catheter Ablation of Atrial Fibrillation</title><p>Lijuan Wang<sup>1</sup>, Min Wang<sup>2*</sup>, Dongsi Shuang<sup>2</sup></p><p><sup>1</sup>Wuhan Medical College of Science and Technology, Wuhan Hubei</p><p><sup>2</sup>Wuhan Asian visceral Disease Hospital, Wuhan Hubei</p><p><img src="//html.hanspub.org/file/4-1571526x4_hanspub.png" /></p><p>Received: Aug. 18<sup>th</sup>, 2020; accepted: Sep. 2<sup>nd</sup>, 2020; published: Sep. 9<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/4-1571526x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Patients with atrial fibrillation are at risk for thromboembolic events (cerebrovascularembolicevents, CVEs), including stroke and transient ischemic attacks. Anticoagulant therapy (oralanticoagulation therapy, OAT) can effectively prevent CVE, catheter ablation (catheterablation, CA) in the treatment of atrial fibrillation has become the most effective rhythm control strategy for some patients. Although retrospective studies have suggested that eliminating atrial fibrillation or reducing the burden of atrial fibrillation through CA may significantly reduce stroke risk, whether OAT can be stopped safely after successful catheter ablation is still a controversial topic.</p><p>Keywords:Atrial Fibrillation, Catheter Ablation, Anticoagulant, Stroke</p><disp-formula id="hanspub.37531-formula23"><graphic xlink:href="//html.hanspub.org/file/4-1571526x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1571526x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-1571526x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>心房颤动(房颤)仍然是世界范围内最常见的心律失常，有证据表明发病率和患病率稳步上升 [<xref ref-type="bibr" rid="hanspub.37531-ref1">1</xref>]。在中国，20岁以上人群中房颤的发病率为0.2%，总体上每年房颤的发病率为0.05%。11年来，房颤的患病率增加了20倍，而与房颤相关的中风增加了13倍 [<xref ref-type="bibr" rid="hanspub.37531-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.37531-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.37531-ref4">4</xref>]。在非瓣膜性房颤患者中，卒中风险大约增加了5倍 [<xref ref-type="bibr" rid="hanspub.37531-ref5">5</xref>]。此外，Bjorck等人报告说，卒中风险随着年龄的增长而增加，报告显示年龄在50到59岁人群卒中新发病率为4.6%，而80岁到89岁的人群中超过20% [<xref ref-type="bibr" rid="hanspub.37531-ref6">6</xref>]。因此，预防卒中是房颤的主要治疗方法。</p><p>窦性心律的恢复和维持被认为比单纯的心率控制更有利于房颤患者的预后 [<xref ref-type="bibr" rid="hanspub.37531-ref7">7</xref>]。射频导管消融术已成为获取窦性心律的主要方法，在全世界范围内越来越多地被应用于临床中，特别是在抗心律失常药物治疗失败患者中，提高了患者生活质量。房颤消融对CVE风险的长期影响尚不清楚。目前大多数指南或共识建议，CA术前血栓事件的高危患者，即CH2ADS2-VASc评分超过2分的患者，在CA术后应继续服用OAC很长一段时间，甚至终身服用。这一策略降低了缺血性血管事件的发生率，同时增加了轻微和大量出血的风险，这通常是危及生命的。本综述的目的是根据国内外研究展示当前支持和反对房颤消融成功后是否继续OAT的证据，为临床管理实践提供指导建议。</p></sec><sec id="s6"><title>2. 心房颤动和卒中的病理生理学</title><p>尽管房颤和缺血性卒中之间的流行病学联系已经确立，但具体的发病机制仍存在争议。长期以来，占主导地位的理论是房颤诱发的左心房血流淤滞导致血栓形成和栓塞。然而，最近的证据指出了一种更复杂的关系，包括心房结构中广泛的基质变化，称为心房心脏病 [<xref ref-type="bibr" rid="hanspub.37531-ref8">8</xref>]。该理论认为，心房纤维化和功能障碍会增加卒中风险，而房颤只是一种附带现象。房颤发作和心源性栓塞事件之间缺乏时间相关性支持了这一理论 [<xref ref-type="bibr" rid="hanspub.37531-ref9">9</xref>]。此外，CHA2DS2-VASc评分通常被认为是心血管疾病负担的预测因子，而不是房颤卒中风险的预测因子。在一项来自加拿大的大型前瞻性注册研究中，CHA2DS2-VASc评分可以有效预测无房颤患者的缺血性卒中 [<xref ref-type="bibr" rid="hanspub.37531-ref10">10</xref>]。通过结合房性心脏病程度的生理参数，CHA2DS2-VASc评分的能力可能得到提高。例如，一项包括67875名患者的9项队列研究的大型荟萃分析显示，左心房大小与缺血性卒中的风险密切相关 [<xref ref-type="bibr" rid="hanspub.37531-ref11">11</xref>]。除了传统的评分系统外，影像学方面的最新进展有助于将心房纤维化确定为卒中的一个增量风险因素 [<xref ref-type="bibr" rid="hanspub.37531-ref12">12</xref>]。房颤消融成功对左房大小和纤维化的影响，除了减少房颤负荷外，还可能潜在地调节消融后卒中的风险。</p></sec><sec id="s7"><title>3. 心房颤动导管消融期后口服抗凝治疗</title><p>最新的2017年HRS/EHRA/ECAS/APHRS/SOLAECA关于房颤导管和外科消融的专家共识声明建议，消融期(即术后2~3个月)后是否继续全身抗凝的决定应该主要基于患者的CVE风险概况，而不是消融过程的成功或失败(I-C)。特别是，该声明建议CHA2DS2-VASc评分 ≥ 2男性患者或≥3的女性患者消融后终生抗凝治疗。同时，指南还建议对于只有一个卒中风险因素的患者(例如CHA2DS2-VASc评分男性1分或女性2分)，OAT的作用处于“边界”，在消融后可以考抗凝。最后，对于低卒中风险的患者(如男性CHA2DS2-VASc 0或女性 ≤ 1)，房颤消融后一般不推荐使用OAT，除非预期进行或最近进行了复律 [<xref ref-type="bibr" rid="hanspub.37531-ref13">13</xref>]。但这些建议是在没有大量数据可用于指导房颤消融患者的OAT治疗的情况下提出的，需要进一步的临床试验来确定长期卒中风险和AF消融后持续OAT的必要性。</p><sec id="s7_1"><title>3.1. 关于导管消融后与卒中风险降低相关的研究</title><p>有几项回顾性研究表明房颤消融后CVE的发生率很低，提示消除AF可能会降低CVE的风险。瑞典的一项注册性研究纳入361,913名诊断为AF的患者。在7年的时间里，在4278个人中进行了5176次AF消融。在消融组中，有78例患有缺血性卒中，而未消融组为112例(年率0.70对1.0%，P = 0.013)。共有88例消融患者和184例未消融患者死亡(年率0.77对1.62%，P &lt; 0.001)。经过多变量调整后，导管消融与缺血性卒中的风险较低[危险比(HR) 0.69，95%置信区间(CI) (0.51~0.93)和较低的死亡风险(HR 0.50，95% CI 0.37~0.62)相关。在CHA2DS2-VASc评分 ≥ 2的患者(HR 0.39，95%CI 0.19~0.78)和消融后6个月以上没有新的心脏复律的患者中风减少最为明显(HR 0.68，95%CI 0.48~0.97)。作者得出结论：消融可能与房颤患者缺血性卒中和死亡的发生率降低有关。在血栓栓塞风险较高的患者中，这一有益发现显得更为明显 [<xref ref-type="bibr" rid="hanspub.37531-ref14">14</xref>]。</p><p>Saliba [<xref ref-type="bibr" rid="hanspub.37531-ref15">15</xref>] 等人对969名接受房颤消融术的房颤患者进行了队列研究，并将结果与3772名未接受房颤消融术的房颤患者的倾向匹配组进行了比较，发现在这一主要为高危患者的组中(83.4%的CHA2DS2-VASc评分 ≥ 2)，接受消融术治疗的患者比未接受房颤消融术的患者在随访期间出现CVE的可能性更小(HR 0.61，95% CI 0.48~0.79)。</p><p>在最近发表的具有里程碑意义的CABANA (心房颤动的导管消融与抗心律失常药物治疗)试验中，2204名有症状的房颤患者随机接受消融或抗心律失常药物治疗，卒中致残的发生率(0.3%:0.6%; p = 0.38)或严重出血(3.2% vs. 3.3%; p = 0.93)没有显著差异。然而，考虑到事件发生率很低，这项研究无法确定导管消融是否真的降低了房颤患者的长期卒中风险 [<xref ref-type="bibr" rid="hanspub.37531-ref16">16</xref>]。</p></sec><sec id="s7_2"><title>3.2. 关于导管消融后停止抗凝的研究</title><p>许多关于房颤消融后停止OAT后CVE发生率的回顾性研究已经发表。在其中一项研究中，Sjalander [<xref ref-type="bibr" rid="hanspub.37531-ref17">17</xref>] 等人报道了来自瑞典的一项大型回顾性队列研究的结果，该研究分析了4364例接受房颤消融的房颤患者，其中703例CHA2DS2VASc评分 ≥ 2。在703例CVE高危患者中，106例(15.1%)患者在消融后停止华法林治疗，5例(4.7%)患者在随访中发生CVE。对比消融后停止和继续使用OAT的患者，他们确定了卒中的独立预测因子包括CHA2DS2-VASc ≥ 2 (HR4.6；95%CI 1.2~17.2；p = 0.02)和既往缺血性卒中病史(HR13.7；95%CI 2.0~91.9；p = 0.07)。鉴于停止OAT的高危患者的卒中发生率较高，作者建议对既往有缺血性卒中病史的CHA2DS2-VASc评分 ≥ 2的患者终生进行OAT。在他们的研究中，在随访期间发生CVE的11名患者中，有8名(72.7%)在手术后进行了心脏复律或术后重复房颤消融。重要的是，整个研究队列中超过60%的人进行了复律或重复房颤消融，而且由于该研究仅通过需要复律或重复消融来确定房颤复发，而不是心电图监测数据或症状记录，房颤复发的真实发生率可能有明显的漏检 [<xref ref-type="bibr" rid="hanspub.37531-ref18">18</xref>]。因此，这项研究没有具体回答房颤消融成功的患者是否可以安全地停止OAT的问题。</p><p>Thermisoclakis等人报道了对3355例房颤消融患者的大型多中心回顾性研究，其中2692例患者在消融后3~6个月停止抗凝。他们发现，超过28个月的平均随访时间里，停用OAC的患者卒中发生率极低(0.07%)，而继续服用OAC的患者中有2%发生大出血事件 [<xref ref-type="bibr" rid="hanspub.37531-ref19">19</xref>]。最近Liang [<xref ref-type="bibr" rid="hanspub.37531-ref20">20</xref>] 等人通过对400例首次接受房颤消融治疗的非阵发性房颤患者(200例持续性房颤，200例长期持续性房颤)进行随访分析，评估了在房颤无复发的患者中OAT是否可以安全停止，并检查了接受导管消融治疗的非阵发性房颤患者的卒中和大出血事件的长期发生率。对这些患者随访3.6 &#177; 2.4年。随访结束时，172例(43.0%)患者无房颤复发。房颤未复发患者中69%的患者在平均3.6年后停止了OAT (HR 0.23)。消融前持续性房颤患者与长期持续性房颤患者(心率0.6)以及CHAO2D 2-VaSC评分 &lt; 2 (心率0.56)的患者不太可能继续接受OAC治疗。共有7名患者发生心血管事件(发病率：0.49/100患者/年)，14名患者在随访期间出现大出血(发病率：0.98/100名患者/年)。作者得出结论，在成功消融非阵发性房颤后密切监测的患者中，选择终止抗凝的患者临床卒中发生率较低。在最近的一项对5项研究的荟萃分析中，Romero和他的同事 [<xref ref-type="bibr" rid="hanspub.37531-ref21">21</xref>] 相似地报告了持续OAC对高风险患者的有益影响。在这项分析中CHA2DS2-VASc评分为2或更高的患者CA术后3个月以上继续使用抗凝药物血栓栓塞风险相对降低59%相关。然而，颅内出血的风险在统计上也有显著增加。我国的于 [<xref ref-type="bibr" rid="hanspub.37531-ref22">22</xref>] 等人最近的一项多中心、回顾性研究对阵发性心房颤动(AF)导管消融后中止口服抗凝药的现状进行调查。得出类似的结论：停止OAT的阵发性AF患者不良事件的发生率相对较低。患者部分确定何时停用口服抗凝药物(Oral anticoagulant，OAC)。在许多未停止OAC的患者中未达到目标INR。</p><p>Romero [<xref ref-type="bibr" rid="hanspub.37531-ref23">23</xref>] 等人对房颤导管消融后的OAT进行了系统回顾和荟萃分析。他们发现持续OAT与高风险队列中血栓栓塞事件(TE)的风险显著降低相关。在低风险队列中未观察到持续OAC疗法的显著益处。OAC组颅内出血明显较高。</p><p>最近美国的一项大型登记实验 [<xref ref-type="bibr" rid="hanspub.37531-ref24">24</xref>]，在21595例患者中，1190例(6%)接受了房颤消融。队列包括1087名接受房颤消融的患者和1087名仅接受抗心律失常药物治疗的患者，比例为1:1。在接受房颤消融的患者中(男性CHA2DS2VASc评分为≥2，女性为≥3) 23%的患者在消融后停止了房颤。在那些停止使用OAC的患者中，停止使用OAC的中位数时间为6.2个月。他们现仅接受房颤导管消融术和抗心律失常药物治疗的患者在调整后的心血管死亡率或全因死亡率方面没有差异。值得注意的是，尽管指南建议在有中风风险的患者中继续进行卒中预防治疗，但消融后OAC的中断仍然相对常见。</p><p>我国学者杨 [<xref ref-type="bibr" rid="hanspub.37531-ref25">25</xref>] 等人最近进行的一项大型前瞻性、多中心研究，随访4512例房颤消融患者，其中3148例在消融后3个月停用OAC (平均CHA2DS2-VASc得分2.3 &#177; 1.3；有56.9%男性CHA2DS2-VASC得分 ≥ 2 和女性 ≥ 3为“高危”)。应用常规心电图、症状触发心电图和24小时动态心电图密切监测患者房颤复发情况，房颤复发定义为消融后持续时间 &gt; 30 s的持续性房性心律失常。在停用OAT的患者中，血栓栓塞的长期发生率(平均随访时间为24.2个月)极低(每100人年发生0.54起事件)，停用与继续OAT患者的CVE发生率无差异(HR为0.71；95%CI为0.41~1.23；p = 0.21)。然而，在多因素分析中，既往CVE病史(HR 3.4；95%CI 1.92~6.02；p &lt; 0.01)和糖尿病(HR 2.06；95%CI 1.2~3.55；p = 0.01)与CVE风险增加相关。然而梁 [<xref ref-type="bibr" rid="hanspub.37531-ref26">26</xref>] 及Terricabras [<xref ref-type="bibr" rid="hanspub.37531-ref27">27</xref>] 等人发表的社论均指出该研究在实验设计如心电图监测房颤复发及入组患者年龄等存在缺陷，认为研究结论有待考究。</p></sec></sec><sec id="s8"><title>4. 导管消融后复发及监测</title><p>接受房颤导管消融的患者早期和晚期房颤复发的风险增加。不同的作者强调了消融后早期复发的重要性和高发生率 [<xref ref-type="bibr" rid="hanspub.37531-ref28">28</xref>]。Andrade等人的一项汇总分析报告表明，在3个月的消融期的多个研究中，射频消融术后早期复发的发生率在16%~67%之间，平均合并估计约为38% [<xref ref-type="bibr" rid="hanspub.37531-ref29">29</xref>]。Takigawa等人的研究发现尽管导管消融手术成功，但晚期复发更为常见 [<xref ref-type="bibr" rid="hanspub.37531-ref30">30</xref>]。对于卒中高危患者(CHA2DS2-VASc评分 ≥ 2分，女性 ≥ 3分)，在房颤消融明显成功后希望停止OAT的患者，进行长期心律监测可能有助于发现房颤复发。即使在消融前有高度症状的房颤患者，在消融后复发的房颤发作期间，偶尔也会变得症状较少，甚至没有症状。因此，检测房颤复发是很重要的，对于导管消融后停药的患者可以快速识别复发房颤并迅速重启OAT，有可能降低CVE风险。</p><p>消融后可采用多种节律监测策略，其中最具侵入性的是植入式环路记录器(implantable loop recorders, ILR)。其他策略包括例行(每天或每天两次)手动脉搏检查或使用其他技术进行监测，例如可穿戴式心脏监护仪设备或智能手机应用程序，这些应用程序允许患者检查和传输心律，从而增加检测到无症状房颤的可能性 [<xref ref-type="bibr" rid="hanspub.37531-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.37531-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.37531-ref33">33</xref>] [<xref ref-type="bibr" rid="hanspub.37531-ref34">34</xref>]。</p><p>Kaplan等人最近的一项研究检查了21768名未接受抗凝治疗的植入式心血管装置患者 [<xref ref-type="bibr" rid="hanspub.37531-ref35">35</xref>]。正如预期的那样，CHA2DS2-VASc评分与卒中风险直接相关。然而，作者根据设备检测到的房颤持续时间对患者进行进一步的风险分层。他们发现，在CHA2DS2-VASc评分低(0或1)的患者中，无论房颤持续时间长短，CVE风险都非常低。在CHA2DS2-VASc2患者中，房颤阈值 &gt; 24 h的患者CVE风险显著(每年&gt;1%)。CHA2DS2-VASc评分为3分者，房颤持续时间 &gt; 6 min有明显的CVE危险，而CHA2-DS2-VASC评分 ≥ 5分的患者，即使无房颤也有较高的CVE危险性。这些数据支持房颤负荷与CVE风险直接相关的观点。但这项研究的结果强调认识到具有多种卒中危险因素且CHA2DS2-VASc2评分升高的患者即使在没有房颤的情况下也可能发生CVE，这一点非常重要。即长期的OAT不一定能预防与房颤无关的心血管事件(即颈动脉狭窄、微血管疾病、主动脉粥样硬化)。</p></sec><sec id="s9"><title>5. 总结</title><p>综上，目前对于房颤消融后何时安全停止抗凝仍不明确，不同研究结果显示出不同的结论，这可能与CA术后长期OAT存在相当大的实践差异相关。有些患者根据心内科医生评估风险后的建议持续OAT，然而，有症状的消融成功的患者更有可能停止OAT。尽管有数据显示CA与降低AF患者CVE风险相关，到目前为止还没有消融策略显示出令人信服的长期成功率。且目前缺乏强有力的证据支持术后停止OAC的安全性。因此，根据卒中风险评分继续或停止OAT是明智的做法。鉴于正在进行的一项大型随机临床试验OCEAN [<xref ref-type="bibr" rid="hanspub.37531-ref36">36</xref>] 的规模和随机性，影响实践的可能性很大，其结果将进一步阐明这一重要问题，为临床提供最佳的策略。</p></sec><sec id="s10"><title>文章引用</title><p>王丽娟,汪 敏,双东思. 房颤导管消融成功后抗凝Anticoagulation after Successful Catheter Ablation of Atrial Fibrillation[J]. 临床医学进展, 2020, 10(09): 1892-1898. https://doi.org/10.12677/ACM.2020.109284</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37531-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rahman, F., Kwan, G.F. and Benjamin, E.J. (2014) Global Epidemiology of Atrial Fibrillation. Nature Reviews Cardiology, 11, 639-654. &lt;br&gt;https://doi.org/10.1038/nrcardio.2014.118</mixed-citation></ref><ref id="hanspub.37531-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Guo, Y., Tian, Y., Wang, H., et al. (2015) Prevalence, Incidence, and Lifetime Risk of Atrial Fibrillation in China: New Insights into the Global Burden of Atrial Fibrillation. Chest, 147, 109-119. &lt;br&gt;https://doi.org/10.1378/chest.14-0321</mixed-citation></ref><ref id="hanspub.37531-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X., Fu, Q., Song, F., et al. (2018) Prevalence of Atrial Fibrillation in Different Socioeconomic Regions of China and Its Association with Stroke: Results from a National Stroke Screening Survey. International Journal of Cardiology, 271, 92-97. &lt;br&gt;https://doi.org/10.1016/j.ijcard.2018.05.131</mixed-citation></ref><ref id="hanspub.37531-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Jagadish, P.S., Kirolos, I., Khare, S., et al. (2019) Post-Operative Atrial Fibrillation: Should We Anticoagulate? Annals of Translational Medicine, 7, 407. &lt;br&gt;https://doi.org/10.21037/atm.2019.07.10</mixed-citation></ref><ref id="hanspub.37531-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kirchhof, P., Benussi, S., Kotecha, D., et al. (2017) 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS. Revista Española de Cardiología, 70, 50.  
&lt;br&gt;https://doi.org/10.1016/j.rec.2017.07.009</mixed-citation></ref><ref id="hanspub.37531-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bjorck, S., Palaszewski, B., Friberg, L., et al. (2013) Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited: A Population-Based Study. Stroke, 44, 3103-3108. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.113.002329</mixed-citation></ref><ref id="hanspub.37531-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Calkins, H., Kuck, K.H., Cappato, R., et al. (2012) 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-Up, Definitions, Endpoints, and Research Trial Design. Journal of Interventional Cardiac Electrophysiology, 33, 171-257. &lt;br&gt;https://doi.org/10.1007/s10840-012-9672-7</mixed-citation></ref><ref id="hanspub.37531-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Yaghi, S., Boehme, A.K., Hazan, R., et al. (2016) Atrial Cardiopathy and Cryptogenic Stroke: A Cross-Sectional Pilot Study. Journal of Stroke and Cerebrovascular Diseases, 25, 110-114.  
&lt;br&gt;https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.09.001</mixed-citation></ref><ref id="hanspub.37531-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Brambatti, M., Connolly, S.J., Gold, M.R., et al. (2014) Temporal Relationship between Subclinical Atrial Fibrillation and Embolic Events. Circulation, 129, 2094-2099. &lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.113.007825</mixed-citation></ref><ref id="hanspub.37531-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mitchell, L.B., Southern, D.A., Galbraith, D., et al. (2014) Prediction of Stroke or TIA in Patients without Atrial Fibrillation Using CHADS2 and CHA2DS2-VASc Scores. Heart, 100, 1524-1530.  
&lt;br&gt;https://doi.org/10.1136/heartjnl-2013-305303</mixed-citation></ref><ref id="hanspub.37531-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Overvad, T.F., Nielsen, P.B., Larsen, T.B., et al. (2016) Left Atrial Size and Risk of Stroke in Patients in Sinus Rhythm. A Systematic Review. Thrombosis and Haemostasis, 116, 206-219. &lt;br&gt;https://doi.org/10.1160/TH15-12-0923</mixed-citation></ref><ref id="hanspub.37531-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">T andon, K., Tirschwell, D., Longstreth, W.T., et al. (2019) Embolic Stroke of Undetermined Source Correlates to Atrial Fibrosis without Atrial Fibrillation. Neurology, 93, e381-e387. &lt;br&gt;https://doi.org/10.1212/WNL.0000000000007827</mixed-citation></ref><ref id="hanspub.37531-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Calkins, H., Hindricks, G., Cappato, R., et al. (2017) 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation. Heart Rhythm: The Official Journal of the Heart Rhythm Society, 14, e275-e444.</mixed-citation></ref><ref id="hanspub.37531-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Friberg, L., Tabrizi, F. and Englund, A. (2016) Catheter Ablation for Atrial Fibrillation Is Associated with Lower Incidence of Stroke and Death: Data from Swedish Health Registries. European Heart Journal, 37, 2478-2487.  
&lt;br&gt;https://doi.org/10.1093/eurheartj/ehw087</mixed-citation></ref><ref id="hanspub.37531-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Saliba, W., Schliamser, J.E., Lavi, I., Barnett-Griness, O., Gronich, N. and Rennert, G. (2017) Catheter Ablation of Atrial Fibrillation Is Associated with Reduced Risk of Stroke and Mortality: A Propensity Score-Matched Analysis. Heart Rhythm, 14, 635-642. &lt;br&gt;https://doi.org/10.1016/j.hrthm.2017.02.001</mixed-citation></ref><ref id="hanspub.37531-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Packer, D.L., Mark, D.B., Robb, R.A., Monahan, K.H., Bahnson, T.D., Poole, J.E., et al. (2019) Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest among Patients with Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA, 321, 1261-1274.  
&lt;br&gt;https://doi.org/10.1001/jama.2019.0693</mixed-citation></ref><ref id="hanspub.37531-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Själander, S., Holmqvist, F., Smith, J., et al. (2017) Assessment of Use vs Discontinuation of Oral Anticoagulation after Pulmonary Vein Isolationin Patients with Atrial Fibrillation. JAMA Cardiology, 2, 146-152.  
&lt;br&gt;https://doi.org/10.1001/jamacardio.2016.4179</mixed-citation></ref><ref id="hanspub.37531-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Marchlinski, F.E. and Santangeli, P. (2017) When Does High Risk for Stroke Become Low Risk after Atrial Fibrillation Ablation? JAMA Cardiology, 2, 152-154. &lt;br&gt;https://doi.org/10.1001/jamacardio.2016.4228</mixed-citation></ref><ref id="hanspub.37531-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Themistoclakis, S., Corrado, A., Marchlinski, F.E., Jais, P., Zado, E., Rossillo, A., et al. (2010) The Risk of Thromboembolism and Need for Oral Anticoagulation after Successful Atrial Fibrillation Ablation. Journal of the American College of Cardiology, 55, 735-743. &lt;br&gt;https://doi.org/10.1016/j.jacc.2009.11.039</mixed-citation></ref><ref id="hanspub.37531-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Liang, J.J., Elafros, M.A., Mullen, M.T., Muser, D., Hayashi, T., Enriquez, A., et al. (2018) Anticoagulation Use and Clinical Outcomes after Catheter Ablation in Patients with Persistent and Longstanding Persistent Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 29, 823-832. &lt;br&gt;https://doi.org/10.1111/jce.13476</mixed-citation></ref><ref id="hanspub.37531-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Romero, J., Cerrud-Rodriguez, R.C., Diaz, J.C., et al. (2019) Oral Anticoagulation after Catheter Ablation of Atrial Fibrillation and the Associated Risk of Thromboembolic Events and Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Electrophysiology, 30, 1250-1257. &lt;br&gt;https://doi.org/10.1111/jce.14052</mixed-citation></ref><ref id="hanspub.37531-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Yu, R., Xi, H., Lu, J., et al. (2020) Real-World Investigation on Discontinuation of Oral Anticoagulation after Paroxysmal Atrial Fibrillation Catheter Ablation in China. Annals of Palliative Medicine, 9, 940-946.  
&lt;br&gt;https://doi.org/10.21037/apm-20-565</mixed-citation></ref><ref id="hanspub.37531-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Birnie, D.H., Smith, E.E. and Verma, A. (2019) To Continue or Stop Oral Anti-Coagulation in Higher-Risk Patients after a “Successful” AF Ablation; That Is the Question. Journal of Cardiovascular Electrophysiology, 30, 1258-1260.  
&lt;br&gt;https://doi.org/10.1111/jce.14056</mixed-citation></ref><ref id="hanspub.37531-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Freeman, J.V., Shrader, P., Pieper, K.S., et al. (2019) Outcomes and Anticoagulation Use after Catheter Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 12, e007612.  
&lt;br&gt;https://doi.org/10.1161/CIRCEP.119.007612</mixed-citation></ref><ref id="hanspub.37531-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Yang, W.Y., Du, X., Jiang, C., et al. (2020) The Safety of Discontinuation of Oral Anticoagulation Therapy after Apparently Successful Atrial Fibrillation Ablation: A Report from the Chinese Atrial Fibrillation Registry Study. Europace, 22, 90-99. &lt;br&gt;https://doi.org/10.1093/europace/euz235</mixed-citation></ref><ref id="hanspub.37531-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Liang, B., Zhao, Y.X. and Gu, N. (2020) Discontinuation of Oral Anticoagulation Therapy after Apparently Successful Atrial Fibrillation Ablation. Europace, 22, 1143-1144. &lt;br&gt;https://doi.org/10.1093/europace/euaa038</mixed-citation></ref><ref id="hanspub.37531-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Terricabras, M. and Verma, A. (2020) Stopping Oral Anticoagulation after Successful Ablation for Atrial Fibrillation: Reality or Fiction? Europace, 22, 1-2. &lt;br&gt;https://doi.org/10.1093/europace/euz284</mixed-citation></ref><ref id="hanspub.37531-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Liang, J.J., Dixit, S. and Santangeli, P. (2016) Mechanisms and Clinical Significance of Early Recurrences of Atrial Arrhythmias after Catheter Ablation for Atrial Fibrillation. World Journal of Cardiology, 8, 638-646.  
&lt;br&gt;https://doi.org/10.4330/wjc.v8.i11.638</mixed-citation></ref><ref id="hanspub.37531-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Andrade, J.G., Khairy, P., Verma, A., et al. (2012) Early Recurrence of Atrial Tachyarrhythmias Following Radiofrequency Catheter Ablation of Atrial Fibrillation. Pacing and Clinical Electrophysiology, 35, 106-116.  
&lt;br&gt;https://doi.org/10.1111/j.1540-8159.2011.03256.x</mixed-citation></ref><ref id="hanspub.37531-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Takigawa, M., Takahashi, A., Kuwahara, T., et al. (2014) Long-Term Follow-Up after Catheter Ablation of Paroxysmal Atrial Fibrillation: The Incidence of Recurrence and Progression of Atrial Fibrillation. Circulation Arrhythmia and Electrophysiology, 7, 267-273. &lt;br&gt;https://doi.org/10.1161/CIRCEP.113.000471</mixed-citation></ref><ref id="hanspub.37531-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">McManus, D.D., Chong, J.W., Soni, A., Saczynski, J.S., Esa, N., Napolitano, C., et al. (2016) PULSE-SMART: Pulse-Based Arrhythmia Discrimination Using a Novel Smartphone Application. Journal of Cardiovascular Electrophysiology, 27, 51-57. &lt;br&gt;https://doi.org/10.1111/jce.12842</mixed-citation></ref><ref id="hanspub.37531-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Sepehri Shamloo, A., Bollmann, A., Dagres, N., Arya, A. and Hindricks, G. (2020) Smart Watch Devices for Atrial Fibrillation Screening: It Has to Start Somewhere. Journal of the American College of Cardiology, 75, 1364-1365.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2019.10.063</mixed-citation></ref><ref id="hanspub.37531-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Seshadri, D.R., Bittel, B., Browsky, D., Houghtaling, P., Drummond, C.K., Desai, M.Y., et al. (2020) Accuracy of Apple Watch for Detection of Atrial Fibrillation. Circulation, 141, 702-703.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.119.044126</mixed-citation></ref><ref id="hanspub.37531-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Koshy, A.N., Sajeev, J.K., Nerlekar, N., Brown, A.J., Rajakariar, K., Zureik, M., et al. (2018) Smart Watches for Heart Rate Assessment in Atrial Arrhythmias. International Journal of Cardiology, 266, 124-127.  
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2018.02.073</mixed-citation></ref><ref id="hanspub.37531-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Kaplan, R.M., Koehler, J., Ziegler, P.D., Sarkar, S., Zweibel, S. and Passman, R.S. (2019) Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score. Circulation, 140, 1639-1646.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.119.041303</mixed-citation></ref><ref id="hanspub.37531-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Verma, A., Ha, A.C.T., Kirchhof, P., et al. (2018) The Optimal Anticoagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) Trial. American Heart Journal, 197, 124-132.  
&lt;br&gt;https://doi.org/10.1016/j.ahj.2017.12.007</mixed-citation></ref></ref-list></back></article>